<DOC>
	<DOCNO>NCT03087695</DOCNO>
	<brief_summary>Epstein-Barr virus ( EBV ) proven process strong association patient nasopharyngeal carcinoma ( NPC ) . Monitoring plasma EBV DNA NPC patient provide reliable information early detect tumor recurrence risk grouping .</brief_summary>
	<brief_title>Effect Plasma EBV DNA Change During Chemoradiotherapy Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>EBV DNA strongly association NPC patient ' disease status . It provide information disease relapse risk classification . In study , investigate impact plasma EBV DNA concentration change chemoradiotherapy initial tumor response long-term survival patient advance nasopharyngeal carcinoma</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>1 . Histological proven NPC . 2 . 2010 American Joint Committee Cancer ( AJCC ) stage IIIVB . 3 . Age ≧ 20 year old . 4 . Performance status Eastern Cooperative Oncology Group ( ECOG ) ≦ 2 . 5 . Adequate liver , renal , bone marrow function 5.1 Serum total bilirubin level ≦ 2.5 mg/dl . 5.2 Serum creatinine ≦ 1.6 mg/dl calculate creatinine clearance rate ( CCr ) ≧ 60 cc/min . 5.3 White blood cell count ( WBC ) ≧ 3,000/microml . 5.4 Platelet count ≧ 100,000/microml . 6 . Pretreatment plasma EBV DNA &gt; 0 copies/mL 7 . Signed informed consent . 1 . Presence distant metastasis . 2 . Previous radiotherapy chemotherapy . 3 . History malignancy except treated curative intent skin cancer ( melanoma ) , situ cervical cancer , ductal carcinoma situ ( DCIS ) breast . 4 . Severe cardiopulmonary disease ( unstable angina and/or congestive heart failure peripheral vascular disease require hospitalization within last 12 month ; chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization ) clinically significant psychiatric disorder . 5 . Female patient pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>EBV DNA</keyword>
	<keyword>Chemoradiotherapy</keyword>
</DOC>